Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years
Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine (GSK2340274A) in Children Aged 10 to Less Than 18 Years
Sponsor: GlaxoSmithKline
Listed as NCT01035749, this PHASE2 trial focuses on Influenza and remains completed. Sponsored by GlaxoSmithKline, it has been updated 10 times since 2010, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Feb 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .